Headlines about Syros Pharmaceuticals (NASDAQ:SYRS) have trended somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies positive and negative media coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Syros Pharmaceuticals earned a media sentiment score of 0.18 on Accern’s scale. Accern also assigned press coverage about the company an impact score of 46.3039413944154 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
These are some of the media headlines that may have effected Accern’s scoring:
- Wedbush Boosts Syros Pharmaceuticals (SYRS) Price Target to $13.00 (americanbankingnews.com)
- Syros Pharmaceuticals (SYRS) Announces Quarterly Earnings Results, Misses Estimates By $0.01 EPS (americanbankingnews.com)
- BRIEF-Syros Announces Appointment Of Joseph J. Ferra As Chief Financial Officer (reuters.com)
- Syros Announces Appointment of Joseph J. Ferra as Chief Financial Officer (finance.yahoo.com)
- Syros Reports Fourth Quarter and Full Year 2017 Financial Results and Highlights Recent Accomplishments and Anticipated Milestones (finance.yahoo.com)
Syros Pharmaceuticals (SYRS) opened at $12.47 on Wednesday. Syros Pharmaceuticals has a one year low of $6.30 and a one year high of $24.38. The firm has a market cap of $416.25 and a price-to-earnings ratio of -7.17.
SYRS has been the subject of a number of research analyst reports. Cowen restated a “buy” rating on shares of Syros Pharmaceuticals in a report on Monday, December 11th. Oppenheimer set a $28.00 target price on Syros Pharmaceuticals and gave the company a “buy” rating in a report on Monday, January 8th. Zacks Investment Research lowered Syros Pharmaceuticals from a “buy” rating to a “hold” rating and set a $12.00 target price for the company. in a report on Saturday, January 20th. Wedbush increased their target price on Syros Pharmaceuticals from $11.00 to $13.00 and gave the company an “outperform” rating in a report on Tuesday. Finally, BidaskClub upgraded Syros Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday. One analyst has rated the stock with a sell rating, four have assigned a hold rating and six have given a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average target price of $21.13.
In other Syros Pharmaceuticals news, Director Srinivas Akkaraju bought 209,424 shares of the stock in a transaction on Wednesday, January 31st. The shares were purchased at an average cost of $9.55 per share, with a total value of $1,999,999.20. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Jeremy P. Springhorn bought 15,000 shares of the stock in a transaction on Friday, December 15th. The shares were acquired at an average cost of $9.08 per share, for a total transaction of $136,200.00. The disclosure for this purchase can be found here. Insiders bought 334,198 shares of company stock worth $3,127,458 over the last ninety days. 33.60% of the stock is currently owned by company insiders.
About Syros Pharmaceuticals
Syros Pharmaceuticals, Inc is a biopharmaceutical company. The Company offers a gene control platform designed to analyze the unexploited region of deoxyribonucleic acid (DNA) in human disease tissue to identify and drug targets linked to genomically defined patient populations. The Company is focused on developing treatments for cancer and immune-mediated diseases and is building a pipeline of gene control medicines.
Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.